Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial halt

Novartis pauses rap-cel trials after deaths

Analysis based on 7 articles · First reported Sep 01, 2026 · Last updated Sep 04, 2026

Sentiment
-20
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The trial pause raises safety concerns for CAR-T therapies in autoimmune indications, potentially affecting the development timelines and market prospects for Novartis and Bristol Myers Squibb. However, Novartis shares rose 4% as investors prioritized the positive late-stage data for Remibrutinib, indicating the market views the halt as manageable.

Pharmaceuticals Biotechnology

On August 24, 2026, Novartis paused eight clinical trials of its experimental CAR-T cell therapy Rap cell after three patients died from severe, life-threatening immune reactions. The trials targeted autoimmune and neurological disorders including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis, and myasthenia gravis. Novartis is conducting a comprehensive review with independent safety boards and is sharing information with health authorities. Two trials for lymphoma and leukemia were unaffected. Bristol Myers Squibb also voluntarily paused studies of its rival CAR T cell Zola-cel as a precaution. Despite the halt, Novartis shares rose 4% on September 1 as investors focused on the late-stage success of its oral multiple sclerosis drug Remibrutinib.

100 Novartis paused trials
60 Bristol Myers Squibb paused studies
stock
Novartis paused eight Rap cell trials after three patient deaths, triggering a safety review. Despite this, shares rose 4% on positive Remibrutinib data.
Importance 100.0 Sentiment -20.0
stock
Bristol Myers voluntarily paused Zola-cel studies as a precaution, reflecting broader industry caution in CAR-T autoimmune therapies.
Importance 60.0 Sentiment -10.0
oth
Remibrutinib is Novartis' oral MS drug whose late-stage success boosted investor sentiment and offset negative news from the trial halt.
Importance 50.0 Sentiment 80.0
oth
Zola-cel is Bristol Myers' rival CAR T cell, paused voluntarily as a precaution.
Importance 40.0 Sentiment -20.0
cnt
The United States is home to Bristol Myers and health authorities involved in the review.
Importance 20.0 Sentiment 0.0
cnt
Switzerland is the home country of Novartis; the event may affect its pharmaceutical sector reputation.
Importance 20.0 Sentiment 0.0
priv
The The Wall Street Journal first reported the trial halt, bringing public attention to the event.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.